CRDL
Cardiol Therapeutics Inc.
Company Overview
| Mkt Cap | $151.12M | Price | $1.28 |
| Volume | 334.50K | Change | -1.54% |
| P/E Ratio | -4.5 | Open | $1.29 |
| Revenue | -- | Prev Close | $1.30 |
| Net Income | $-33.8M | 52W Range | $0.88 - $1.71 |
| Div Yield | N/A | Target | $6.74 |
| Overall | 59 | Value | 45 |
| Quality | 71 | Technical | 63 |
No chart data available
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Latest News
Cardiol Therapeutics Sets June 24, 2026 Virtual AGM and Adopts Notice-and-Access for Proxy Materials
H.C. Wainwright Keeps Their Buy Rating on Cardiol Therapeutics (CRDL)
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL) and BridgeBio Pharma (BBIO)
Cardiol Therapeutics Reports Higher Q1 2026 Loss but Stronger Cash Position
Cardiol Therapeutics’ Phase II MAvERIC Pericarditis Data Accepted by JAHA as Phase III Trial Nears Completion
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CRDL | $1.28 | -1.5% | 334.50K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Cardiol Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW